美敦力糖尿病业务MiniMed(MMED.US)分拆上市在即估值合理性遭多空激烈交锋

智通财经03-05

智通财经APP获悉，医疗器械巨头美敦力(MDT.US)分拆的糖尿病管理设备制造商MiniMed Group Inc.(MMED.US)即将登陆资本市场，但其增长前景能否支撑此次IPO估值，已在分析师间引发激烈争论。这家总部位于加州北岭的企业计划在周四完成IPO定价，拟最高募资7.84亿美元。文件显示，公司计划进一步拓展胰岛素泵与血糖监测产品，扩大在全球糖尿病市场的覆盖范围。据周三的报道称，尽管...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2617045513?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-05 14:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617045513","market":"hk","top_or_hot":-1,"title":"美敦力糖尿病业务MiniMed(MMED.US)分拆上市在即 估值合理性遭多空激烈交锋","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，医疗器械巨头美敦力(MDT.US)分拆的糖尿病管理设备制造商MiniMed Group Inc.(MMED.US)即将登陆资本市场，但其增长前景能否支撑此次IPO估值，已在分析师间引发激烈争论。这家总部位于加州北岭的企业计划在周四完成IPO定价，拟最高募资7.84亿美元。文件显示，公司计划进一步拓展胰岛素泵与血糖监测产品，扩大在全球糖尿病市场的覆盖范围。据周三的报道称，尽管...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1410376.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美敦力糖尿病业务MiniMed(MMED.US)分拆上市在即 估值合理性遭多空激烈交锋</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美敦力糖尿病业务MiniMed(MMED.US)分拆上市在即 估值合理性遭多空激烈交锋\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-05 14:46 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1410376.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，医疗器械巨头美敦力(MDT.US)分拆的糖尿病管理设备制造商MiniMed Group Inc.(MMED.US)即将登陆资本市场，但其增长前景能否支撑此次IPO估值，已在分析师间引发激烈争论。这家总部位于加州北岭的企业计划在周四完成IPO定价，拟最高募资7.84亿美元。文件显示，公司计划进一步拓展胰岛素泵与血糖监测产品，扩大在全球糖尿病市场的覆盖范围。据周三的报道称，尽管...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1410376.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765489.SGD","symbol_name":"FTIF - Franklin Mutual US Value A Acc SGD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1410376.html","article_id":"2617045513","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617045513","pubTimestamp":1772693193,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，医疗器械巨头美敦力分拆的糖尿病管理设备制造商MiniMed Group Inc.即将登陆资本市场，但其增长前景能否支撑此次IPO估值，已在分析师间引发激烈争论。目前MiniMed的发行已获超额认购，若上市表现亮眼，有望带动更多同行业公司启动IPO。目前，患者主要通过专业医疗设备供应商购买MiniMed产品。其核心产品MiniMed 780G系统，可通过连续血糖监测传感器自动读数，并调节胰岛素输注以控制患者血糖。Marcus对MiniMed发行价中值对应的估值提出质疑。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4588":"碎股","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","MDT":"美敦力","MMED":"MiniMed Group, Inc.","BK4585":"ETF&股票定投概念","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BK4566":"资本集团","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC"},"translate_title":"Medtronic's diabetes business MiniMed (MMED.US) is about to be spun off and listed, and its valuation reasonableness is fiercely confronted by long and short","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDT":1.5,"MMED":1.5},"content_text":"智通财经APP获悉，医疗器械巨头美敦力(MDT.US)分拆的糖尿病管理设备制造商MiniMed Group Inc.(MMED.US)即将登陆资本市场，但其增长前景能否支撑此次IPO估值，已在分析师间引发激烈争论。这家总部位于加州北岭的企业计划在周四完成IPO定价，拟最高募资7.84亿美元。文件显示，公司计划进一步拓展胰岛素泵与血糖监测产品，扩大在全球糖尿病市场的覆盖范围。据周三的报道称，尽管MiniMed已以低于同行的估值向投资者推介，但其IPO认购订单集中在25-28美元发行区间的低端，投资者对价格较为敏感。在医疗防护用品巨头Medline(MDLN.US)完成2025年美国最大规模IPO后，市场对医疗设备新股的热情持续高涨。目前MiniMed的发行已获超额认购，若上市表现亮眼，有望带动更多同行业公司启动IPO。不过，本周伊朗局势持续动荡，市场随时可能重现波动，为本次发行蒙上不确定性。摩根大通分析师Robbie Marcus指出，MiniMed若效仿同行银休特(PODD.US)、Tandem Diabetes Care(TNDM.US)、Beta Bionics(BBNX.US)等，通过药店渠道推广自动胰岛素输注系统，其营收与利润增长将面临挑战。目前，患者主要通过专业医疗设备供应商购买MiniMed产品。知情人士透露，按预期调整后息税折旧摊销前利润计算，MiniMed的估值将低于德康医疗(DXCM.US)、银休特及Tandem等已上市同行。其核心产品MiniMed 780G系统，可通过连续血糖监测传感器自动读数，并调节胰岛素输注以控制患者血糖。Marcus对MiniMed发行价中值对应的估值提出质疑。他在2月25日的客户报告中写道：“我们坚定认为，其合理估值应在20亿-30亿美元区间，最高不超过40亿美元，而本次IPO对应的市值约74亿美元。”“这家企业目前仍处于亏损状态，且短期内难有改善。”文件显示，截至2024年10月24日的六个月内，MiniMed营收15亿美元，净亏损2100万美元;上年同期营收13亿美元，净亏损2300万美元。Robert W.Baird &Co.分析师Jeff Johnson则认为：“从估值角度看，我们对25-28美元的定价区间感到合理。”他表示，这一价格对应的企业价值/过去12个月营收倍数约为2.2-2.5倍，而Tandem为1.8倍，Beta Bionics为3倍。汇编数据显示，去年美国医疗相关IPO募资总额达109亿美元，较2024年增长近三分之二，MiniMed上市将进一步推动医疗IPO回暖。该行另一位分析师David Rescott认为，更多医疗科技公司IPO有望提升板块对投资者的吸引力。他在采访中表示：“近期医疗新股供给不多，像MiniMed这样的新标的会更受青睐，因为它们提供了差异化的投资机会。”加拿大皇家银行分析师Shagun Singh指出，尽管MiniMed分拆上市的时点出乎市场预料，但此举将让美敦力更专注于面向医院的设备业务。她表示：“这笔交易意义重大，因为糖尿病业务正日益向消费端倾斜。”","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617045513","isCrawlerRequest":true}

美敦力糖尿病业务MiniMed(MMED.US)分拆上市在即 估值合理性遭多空激烈交锋

精彩评论

美敦力糖尿病业务MiniMed(MMED.US)分拆上市在即估值合理性遭多空激烈交锋